An iLite^® Reporter Cell Platform to Quantify Anti-AAV Neutralizing Antibodies

The extensive study of AAV vectors as carriers of gene therapy products has advanced the field from a promising new therapeutic concept into today's medical reality. The use of bioassays facilitates the vector potency or determination of neutralizing antibodies (NAbs). 

We present a platform based on the reporter gene assay format that allows us to determine and titrate the presence of NAbs against AAV vectors overnight. This poster presents the proof of concept data for serotype-specific anti-NAbs detection.

The iLite^® AAV-Neutralizing Platform for the assessment of anti-AAV NAbs is a novel tool for rapid and reliable detection of an inhibitory humoral response to the viral vector and was developed to be used in clinical applications.

The newly developed platform can be used to determine the presence of neutralizing antibodies against AAV vectors of different serotypes, showcased here by the use of novel-engineered AAV vector-producing packaging cells in combination with a reporter gene Effector cell.

The modular setup of this platform can also be utilized to design tailored solutions for NAb assessment with next-generation vectors (e.g. hybrid, chimeric, or semi-synthetic capsids).